All In Biotech

Drug Trial Radar · NCT07545681

A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria

A Phase 2A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel Antimalarial Pyrrolidinamide at Different Doses and Dose Durations, in Adult Patients With Uncomplicated P. Falciparum Malaria

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Oct 7, 2026

Primary completion

Oct 8, 2027

Study completion Oct 8, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Apr 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the safety and efficacy of a new antimalarial drug GSK3772701 (a pyrrolidinamide), using different doses and treatment durations, in adult participants with uncomplicated Plasmodium (P.) falciparum malaria.

Conditions

  • Malaria, Falciparum

Interventions

  • GSK3772701 600 mgDrug

    A 600 mg dose of GSK3772701 administered orally, as 4 capsules of 150 mg.

  • GSK3772701 900 mgDrug

    A 900 mg dose of GSK3772701 administered orally, as 6 capsules of 150 mg.

  • GSK3772701 150 mgDrug

    A daily 150 mg dose of GSK3772701 administered orally on Day 1 and Day 2, as 1 capsule.

  • GSK3772701 400 mgDrug

    A daily 400 mg dose of GSK3772701 administered orally on Day 1 and Day 2, as 2 capsules of 150 mg and 1 capsule of 100 mg.

  • GSK3772701 50 mgDrug

    A daily 50 mg dose of GSK3772701 administered orally on Day 1, Day 2 and Day 3, as 1 capsule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with serious adverse events (SAEs) overall, treatment related, and by severityTime frame: From the date of informed consent signing (up to 24 hours prior to Day 1) up to Day 40 (end of the follow-up period)
  2. Number of participants with non-serious AEs overall, treatment related, and by severityTime frame: From Day 1 up to Day 40

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Lambaréné, Gabon · Recruiting

  • GSK Investigational Site

    Kampala, Tororo, Uganda · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.